Functional recovery after percutaneous revascularization of coronary chronic total occlusions: insights from cardiac magnetic resonance tissue tracking

Henk Everaars1 · Stefan P. Schumacher1 · Wijnand J. Stuijfzand1 · Martijn van Basten Batenburg1 · Jennifer Huynh1 · Pepijn A. van Diemen1 · Michiel J. Bom1 · Ruben W. de Winter1 · Peter M. van de Ven2 · Ramon B. van Loon1 · Albert C. van Rossum1 · Maksymilian P. Opolski3 · Alexander Nap1 · Paul Knaapen1

Received: 25 February 2021 / Accepted: 7 July 2021 / Published online: 2 August 2021
© The Author(s) 2021

Abstract
To evaluate the effect of percutaneous coronary intervention (PCI) of coronary chronic total occlusions (CTOs) on left ventricular (LV) strain assessed using cardiac magnetic resonance (CMR) tissue tracking. In 150 patients with a CTO, longitudinal (LS), radial (RS) and circumferential shortening (CS) were determined using CMR tissue tracking before and 3 months after successful PCI. In patients with impaired LV strain at baseline, global LS (10.9 ± 2.4% vs 11.6 ± 2.8%; P = 0.006), CS (11.3 ± 2.9% vs 12.0 ± 3.5%; P = 0.002) and RS (15.8 ± 4.9% vs 17.4 ± 6.6%; P = 0.001) improved after revascularization of the CTO, albeit to a small, clinically irrelevant, extent. Strain improvement was inversely related to the extent of scar, even after correcting for baseline strain (B = −0.05; P = 0.008 for GLS, B = −0.06; P = 0.016 for GCS, B = −0.13; P = 0.017 for GRS). In the vascular territory of the CTO, dysfunctional segments showed minor improvement in both CS (10.8 [6.9 to 13.3] % vs 11.9 [8.1 to 15.0] %; P < 0.001) and RS (14.2 [8.4 to 18.7] % vs 16.0 [9.9 to 21.8] %; P < 0.001) after PCI. Percutaneous revascularization of CTOs does not lead to a clinically relevant improvement of LV function, even in the subgroup of patients and segments most likely to benefit from revascularization (i.e. LV dysfunction at baseline and no or limited myocardial scar).

Keywords Coronary occlusion · Magnetic resonance imaging · Ventricular function, left · Percutaneous coronary intervention

Abbreviations
CAD Coronary artery disease
CMR Cardiac magnetic resonance imaging
CTO Coronary chronic total occlusion
(G)CS (Global) circumferential shortening
GLS Global longitudinal shortening
(G)RS (Global) radial shortening
ICC Intraclass correlation coefficients
LGE Late gadolinium enhancement
LV Left ventricular
PCI Percutaneous coronary intervention
TIMI Thrombolysis in myocardial infarction

Introduction
Coronary chronic total occlusions (CTOs) are present in approximately 1 in 4 patients with obstructive coronary artery disease (CAD) on invasive coronary angiography [1]. The presence of a CTO confers unfavorable prognosis, with higher rate of major adverse cardiovascular events including death [2]. Contemporary guidelines consider the treatment of CTO lesions analogous to that of non-CTO lesions, indicating that revascularization is recommended for relieving symptoms in patients with refractory angina refractory and for improving prognosis in patients with a large area of viable myocardium at risk [3]. Percutaneous coronary intervention (PCI) of CTO lesions however comes at the expense of higher contrast use, longer fluoroscopy time and increased
complication rates in comparison with non-CTO lesions [4]. In addition, CTO-PCI did not improve outcome compared with conservative treatment in 3 recent randomized trials [5–7]. The benefit of CTO-PCI is therefore controversial and careful selection of patients is required before attempting revascularization. Functional recovery of hibernating, viable myocardium is one of the potential benefits of CTO-PCI. Cardiac magnetic resonance imaging (CMR) is considered the gold standard for quantifying cardiac function and has been extensively used to study functional recovery after CTO-PCI, with conflicting results [8–19]. Furthermore, no differences in regional function in the CTO territory between patients treated with CTO-PCI versus patients receiving optimal medical therapy only was observed [11]. Importantly, prior studies used left ventricular (LV) ejection fraction and analysis of wall thickening to measure global and regional function, respectively. Assessment of myocardial strain using CMR tissue tracking has been proposed as a more sensitive method to measure LV dysfunction [20]. Myocardial strain provides prognostic information incremental to LV ejection fraction and is superior to wall thickening in quantifying regional myocardial function [20, 21]. Therefore, the aim of the present study was to evaluate the effect of CTO-PCI on global and regional myocardial strain assessed using CMR tissue tracking.

Materials and methods

Study population and design

Consecutive patients with a CTO of a native coronary artery referred to the Amsterdam University Medical Center were prospectively enrolled between 2013 and 2018. CTO was defined as a vessel with Thrombolysis In Myocardial Infarction (TIMI) flow grade 0 or 1 with an estimated duration of ≥ 3 months. Baseline CMR was performed prior to CTO-PCI in all patients and follow-up CMR was scheduled 3 months after successful percutaneous revascularization. Exclusion criteria were recent myocardial infarction, concomitant non-ischemic cardiomyopathy and non-diagnostic baseline or follow-up CMR cine images. Since myocardial strain values are dependent on acquisition method and post-processing software, 100 healthy volunteers without a history of cardiovascular disease underwent CMR to calculate normal values. The study was approved by the Institutional Review Board of the Amsterdam University Medical Center, location VUmc. All subjects provided written informed consent.

CMR image acquisition

CMR was performed in all subjects on a 1.5-T clinical scanner (Magnetom Avanto, Siemens Healthineers) using identical imaging parameters. Cine images were obtained using a balanced steady-state free-precession sequence in the 2-, 3- and 4-chamber long-axis views and multiple short-axis views covering the entire LV from base to apex. Typical imaging parameters were: echo time, 1.5 ms; repetition time, 3.2 ms; α, 60 to 80°; spatial resolution, 1.6 × 1.6 mm; slice thickness, 5 mm; gap, 5 mm; temporal resolution, 30 to 50 ms. For assessment of myocardial scar, late gadolinium enhancement (LGE) images were obtained 10 to 15 min after administration of 0.2 mmol/kg of a gadolinium-based contrast agent (Dotarem®, Guerbet) using a segmented inversion recovery gradient-echo pulse sequence. Slice positions of the LGE images were identical to those of the cine images. Typical imaging parameters were: echo time, 4.4 ms; repetition time, 9.6 ms; α, 25°; spatial resolution, 1.6 × 1.6 mm; slice thickness, 5 mm; inversion time, 250 to 350 ms.

CMR image analysis

CMR analysis was performed by a single observer (H.E.) blinded to all clinical data, angiographic data and timing of imaging. Conventional analysis of cine and LGE images was performed using QMass software (version 7.6, Medis Medical Imaging Systems). LV ejection fraction, mass and volumes were calculated from the short-axis cine images. Infarct size was determined from the LGE images using the full-width-at-half maximum method, followed by manual correction [22]. Analysis of myocardial strain was performed using CMR32 software (version 5.11, Circle Cardiovascular Imaging Inc.). Endo- and epicardial contours were manually drawn on the end-diastolic and end-systolic phases and reference points for segmentation were manually defined at the anterior- and inferior RV insertion points. In line with prior reports, longitudinal and circumferential strain were expressed as absolute, positive values and the term shortening instead of strain was used [23]. Global longitudinal shortening (GLS) was calculated from the 3 long-axis cine views. Global circumferential and radial shortening (GCS and GRS, respectively) were calculated from the short-axis cine views. For regional analysis, the LV was divided into 16 segments (true apex not included) according to the segmentation model of the American Heart Association (AHA) [24]. A single observer (S.S) assessed coronary dominance using the invasive coronary angiogram. Segments were subsequently assigned to coronary arteries.
by H.E. accounting for dominance. In a right dominant system, the standard segmentation model of the AHA was used [24]. In a co-dominant system, segments 4 and 10 were transferred from the RCA to the Cx. In a left dominant system, segments 3, 4, 9, 10 and 15 were all transferred from the RCA tot the Cx as the RCA does not supply the left ventricle. Remote myocardium was defined as the myocardial segments opposite to the vascular territory of the CTO. Remote myocardium was only included in analysis if the myocardial segments showed no hyperenhancement and the supplying coronary vessel had < 50% diameter stenosis. Circumferential and radial shortening (CS and RS, respectively) as well as percentage of hyperenhancement were calculated for each segment. Segments with > 50% hyperenhancement were considered non-viable. Cut-off values for global strain were determined by calculating the fifth percentile of GLS, GCS and GRS in the cohort of healthy volunteers. Given that strain values are independent of initial segment length, impaired regional strain was defined using the same cut-off parameters as used for global strain. The percentage of LV that was dysfunctional but viable was calculated for every patient by dividing the number of segments with ≤ 50% LGE and impaired strain by 16 and multiplying this value with 100. CMR strain analysis was repeated by the first observer (H.E) as well as a second observer (M.B.) in 50 randomly selected scans to assess intra- and interobserver variability, respectively.

Statistical analysis

Pearson’s and spearman’s correlations were used to quantify association between normally and non-normally distributed continuous data, respectively. Reproducibility of CMR strain measurements was evaluated by intraclass correlation coefficients (ICCs) and Bland–Altman analysis. ICCs for absolute agreement of single measures were estimated using a two-way random effects model. Paired samples T-tests were used to compare global strain and scar size before and after CTO-PCI. Association between extent of scar and global strain improvement was tested using analysis of covariance with global strain improvement as dependent variable and correcting for global strain at baseline. On a segmental level, means of strain before and after CTO-PCI were compared using a linear mixed model with a fixed effect for imaging timing and random effects for patient and segment nested within patient. All statistical tests were two tailed and a p value of < 0.05 was considered statistically significant. Statistical analysis was done with SPSS (version 26 for Windows, IBM).

Results

Characteristics of the study population

Figure 1 displays the flowchart of the study population. A total of 275 patients underwent CMR. CTO-PCI was attempted in 237 (86%) patients and paired CMR images were available in 158 (57%) patients. Eight patients were excluded post-hoc (reasons presented in Fig. 1) resulting in a final sample size of 150 patients. Table 1 lists the baseline characteristics of the study cohort and Table 2 lists angiographic characteristics. Median time between PCI and follow-up CMR was 101 [94 to 117] days.

CMR assessment of myocardial scar

Although only 30 (20%) patients had a documented prior myocardial infarction related to the CTO vessel, CMR revealed hyperenhancement in the vascular territory of the CTO in 112 (75%) patients. Median scar size was 4.4 [1.0 to 10.4] % before revascularization and increased to 5.0 [2.1 to 14.4] % after (P < 0.001).

Reproducibility of strain measurements

Global and regional strain measurements had excellent intra- and interobserver reproducibility (Table 3). Bland–Altman plots demonstrated no significant bias and narrow limits of agreement (Supplementary Figs. 1 and 2).

Strain in healthy volunteers

In the cohort of healthy volunteers, GLS ranged from 13.3% to 21.7% with a mean 17.6 ± 1.8%, GCS from 13.6% to 23.3% with a mean of 18.5 ± 2.2% and GRS from 20.8% to 46.1% with a mean of 31.3 ± 6.1% (data presented in Supplementary Table 1). Impaired global and radial strain were defined as LS < 14.4%, CS < 15.0% and RS < 22.1%.

Global LV function

GLS, GCS and GRS correlated strongly with LV ejection fraction (r = 0.86; P < 0.001 for GLS, r = 0.93; P < 0.001 for GCS, r = 0.90; P < 0.001 for GRS) and inversely with the extent of myocardial scar (ρ = −0.59; P < 0.001 for GLS, ρ = −0.64; P < 0.001 for GCS, ρ = −0.63; P < 0.001 for GRS) (Supplementary Fig. 3). GLS was impaired in 62 (41%) patients, GCS in 60 (40%) patients and GRS in 58 (39%) patients. A total of 51 (34%) patients had impaired LV strain, defined as the...
combination of impaired GLS, GCS and GRS. Table 4 presents global LV function before and after PCI. In the overall population, CTO-PCI resulted in a small but significant improvement in LV ejection fraction and a reduction in LV volumes. In contrast, GLS, GCS and GRS did not improve after CTO-PCI. The subgroup of patients with impaired strain at baseline however demonstrated an increase in GLS, GCS and GRS. Figure 2 depicts a case example of a patient with impaired LV function at baseline in whom strain markedly improved after CTO-PCI. Notably, GLS decreased in patients with preserved strain at baseline while no significant changes in GCS, GRS or LV ejection fraction were observed. Figure 3 shows the relationship between global strain improvement and the extent of viability (i.e. the percentage of the LV that was dysfunctional but viable). Strain improvement correlated significantly with the extent of viability, defined by either CS or RS. In addition, the improvements in strain after CTO-PCI were inversely related to the extent of scar, even after correcting for baseline strain (B = −0.05; P = 0.008 for GLS, B = −0.06; P = 0.016 for GCS, B = −0.13; P = 0.017 for GRS).
Regional LV function

Segmental CS and RS correlated inversely with the percentage of scar ($\rho = -0.48$; $P < 0.001$ for CS, $\rho = -0.47$; $P < 0.001$ for RS, Supplementary Fig. 4). Table 5 presents regional strain before and after PCI-CTO stratified according to baseline strain and extent of hyperenhancement. Analysis of all segments in the vascular territory of the CTO revealed a significant increase in CS, but not in RS. In segments with impaired strain at baseline, both CS and RS increased after CTO-PCI. Conversely, CS and RS decreased in segments with preserved strain at baseline. Revascularization had no effect on strain in remote myocardium. Surprisingly, dysfunctional segments with $>50\%$ hyperenhancement demonstrated an increase in CS and RS at follow-up. Although baseline strain was significantly lower in dysfunctional segments with $>50\%$ hyperenhancement compared with dysfunctional segments with $\leq 50\%$ hyperenhancement, the improvement in CS (1.3 $[-0.2$ to 5.2] $\%$ vs 1.8 $[-0.4$ to 4.2] $\%$; $P=0.37$) and RS (1.5 $[-0.1$ to 6.6] $\%$ vs 2.8 $[-0.8$ to 6.7] $\%$; $P=0.97$) was similar (Fig. 4).

**Discussion**

The present study is the largest thus far to investigate functional recovery after CTO-PCI using CMR, which is considered the gold standard for assessment of myocardial function. The main findings of our study can be summarized as follows: (1) CTO-PCI did not improve global longitudinal, circumferential and radial shortening; (2) CTO-PCI resulted in a small but significant improvement of global strain in patients with impaired LV function; (3) This improvement was primarily driven by strain recovery in dysfunctional myocardium in the vascular territory of the CTO.

Previous CMR studies investigating functional improvement after CTO-PCI have shown conflicting results. While some studies reported an increase in LV ejection fraction after CTO-PCI, others found no improvement in LV function [8–19]. Interestingly, mean LV ejection fraction prior to revascularization was well preserved (i.e. $>60\%$) in studies that failed to demonstrate improvement [8–11]. Conversely, mean baseline LV ejection fraction was impaired in most studies showing an increase in global function [12–19]. Logically, the presence of LV dysfunction appears to be a prerequisite for functional improvement. On a regional level, wall thickening in the vascular territory of the CTO also improves predominantly in segments with hypo- or akinesia at baseline [11]. In addition to LV dysfunction, the presence of viable myocardium has been described as a second prerequisite for functional recovery. Dysfunctional segments with limited or no scar have a high likelihood of improvement, whereas LV function is unlikely to recover in myocardium with transmural infarction [25]. It is therefore imperative to perform both cine and LGE imaging when using CMR to select patients who may benefit from revascularization in terms of functional improvement. Several studies in patients with a CTO reported that LGE imaging aids in predicting functional recovery after PCI [8, 15, 16]. However, Stuijfzand et al. and Fiocchi et al. found no relationship

| Variables | N = 150 |
|-----------|---------|
| Age (years) | $63 \pm 11$ |
| Male | 124 (83) |
| Body mass index (kg/m$^2$) | 27 $\pm 4$ |
| Risk factors | |
| Family history of CAD | 67 (45) |
| Hypertension | 75 (50) |
| Dyslipidemia | 66 (44) |
| Diabetes mellitus | 37 (25) |
| Smoking | 111 (74) |
| Peripheral artery disease | 22 (15) |
| Cardiac history | |
| Prior documented MI | 73 (49) |
| Prior documented MI in CTO territory | 30 (20) |
| Prior PCI | 104 (69) |
| Prior PCI in CTO vessel | 28 (19) |
| Prior CABG | 17 (11) |
| Prior CABG on CTO vessel | 13 (9) |
| CCS class | |
| No angina | 78 (52) |
| I | 6 (4) |
| II | 45 (30) |
| III | 18 (12) |
| IV | 3 (2) |
| NYHA class | |
| I | 84 (56) |
| II | 36 (24) |
| III | 29 (19) |
| IV | 1 (1) |
| Medication | |
| Aspirin | 136 (91) |
| P2Y12 inhibitor | 101 (67) |
| ACE inhibitor or ATII antagonist | 79 (53) |
| Beta-blocker | 115 (77) |
| Calcium channel blockers | 32 (21) |
| Long-acting nitrates | 119 (79) |
| Statin | 124 (83) |

Data are mean $\pm$ standard deviation or absolute number (%). CABG = coronary artery bypass grafting; CAD = coronary artery disease; CCS = Canadian Cardiovascular Society; CTO = chronic total occlusion; MI = myocardial infarction; NYHA = New York Heart Association; PCI = percutaneous coronary intervention.
| Variables                                   | All patients (n = 150) | with preserved strain (n = 81) | with impaired strain (n = 51) | P value |
|--------------------------------------------|------------------------|-------------------------------|-------------------------------|---------|
| CTO vessel                                 |                        |                               |                               | 0.38    |
| RCA                                       | 105 (70)               | 55 (68)                       | 37 (73)                       |         |
| LAD                                        | 32 (21)                | 20 (25)                       | 8 (16)                        |         |
| LCx                                        | 13 (9)                 | 6 (7)                         | 6 (12)                        |         |
| CTO characteristics                       |                        |                               |                               |         |
| Blunt stump                                | 42 (28)                | 18 (22)                       | 18 (35)                       | 0.28    |
| Occlusion length ≥ 20 mm                   | 82 (55)                | 31 (38)                       | 23 (45)                       | 0.44    |
| Severe calcification                       | 88 (59)                | 40 (49)                       | 36 (71)                       | 0.11    |
| Bending > 45°                              | 57 (38)                | 36 (44)                       | 15 (29)                       | 0.21    |
| Ostial location                            | 13 (9)                 | 9 (11)                        | 2 (4)                         | 0.15    |
| Previous failed PCI attempt                | 25 (17)                | 15 (19)                       | 7 (14)                        | 0.47    |
| J-CTO score                                |                        |                               |                               | 0.27    |
| 0–1                                        | 56 (37)                | 35 (43)                       | 17 (33)                       |         |
| 2                                          | 49 (33)                | 23 (28)                       | 19 (37)                       |         |
| ≥ 3                                        | 45 (30)                | 23 (28)                       | 15 (29)                       |         |
| Collateral collection score                |                        |                               |                               | 0.52    |
| 0                                          | 6 (4)                  | 4 (5)                         | 3 (6)                         |         |
| 1                                          | 41 (27)                | 22 (27)                       | 17 (33)                       |         |
| 2                                          | 103 (69)               | 55 (68)                       | 31 (61)                       |         |
| Rentrop grade                              |                        |                               |                               | 0.55    |
| 0–1                                        | 1 (1)                  | 1 (1)                         | 0 (0)                         |         |
| 2                                          | 20 (13)                | 10 (12)                       | 10 (20)                       |         |
| 3                                          | 129 (86)               | 70 (86)                       | 41 (80)                       |         |
| Extent of CAD                              |                        |                               |                               | 0.02    |
| 1-vessel disease                           | 101 (67)               | 61 (75)                       | 27 (53)                       |         |
| 2-vessel disease                           | 42 (28)                | 18 (22)                       | 19 (37)                       |         |
| 3-vessel disease                           | 7 (5)                  | 2 (3)                         | 5 (10)                        |         |
| Successful PCI strategy                    |                        |                               |                               | 0.61    |
| AWE                                        | 65 (43)                | 35 (43)                       | 24 (47)                       |         |
| ADR                                        | 31 (21)                | 18 (22)                       | 7 (14)                        |         |
| RWE                                        | 19 (13)                | 9 (11)                        | 8 (16)                        |         |
| RDR                                        | 35 (23)                | 19 (24)                       | 12 (24)                       |         |
| Number of implanted stents                 | 2 [2, 3]               | 2 [1–3]                       | 2 [2, 3]                      | 0.10    |
| Total stent length (mm)                    | 83 ± 39                | 82 ± 40                       | 87 ± 37                       | 0.26    |
| Contrast volume (mL)                       | 300 [200–400]          | 300 [200–400]                 | 310 [200–400]                 | 0.57    |
| Fluoroscopy time (min)                     | 33 [18–53]             | 30 [17–51]                    | 31 [21–53]                    | 0.90    |
| Periprocedural adverse events              |                        |                               |                               |         |
| Myocardial infarction                      | 7 (5)                  | 4 (5)                         | 1 (2)                         | 0.38    |
| Coronary perforation                       | 13 (9)                 | 6 (7)                         | 5 (10)                        | 0.63    |
| Tamponade                                  | 3 (2)                  | 2 (3)                         | 1 (2)                         | 0.85    |
| Emergency CABG                             | 0 (0)                  | 0 (0)                         | 0 (0)                         | –       |
| Stroke or TIA                              | 1 (1)                  | 1 (1)                         | 0 (0)                         | 0.43    |
| Death                                      | 0 (0)                  | 0 (0)                         | 0 (0)                         | –       |

Data are mean ± standard deviation, median [interquartile range] or absolute number (%)

ADR antegrade dissection and re-entry, AWE antegrade wire escalation, J-CTO score Japanese chronic total occlusion score, RDR retrograde dissection and re-entry, RWE retrograde wire escalation; other abbreviations as in Table 1
between improvement of regional wall thickening and extent of infarction [13, 17].

In the present study, functional recovery after CTO-PCI was investigated using myocardial strain indices rather than LV ejection fraction and analysis of wall thickening. LV ejection fraction is the cornerstone in the assessment of cardiac function, but is confounded by loading conditions and geometric factors such as LV wall thickness and cavity dimensions [26]. Although myocardial strain is also load dependent, it provides a more accurate assessment of LV function as strain parameters directly quantify myocardial fiber shortening [27]. Myocardial strain imaging is also an auspicious tool to quantify regional function, as conventional analysis of wall thickening suffers from relatively high observer variability due to systolic trabecular infolding [21]. Despite these advantages, myocardial strain imaging using CMR tissue tracking also has shortcomings. Various vendors offer software packages that allow to quantify strain from cine images. In the absence of an industry standard, these software packages use different algorithms with various agreement between the calculated results. In addition, acquisition parameters such as flip angle, spatial and temporal resolution but also the administration of contrast before obtaining the cine images may all influence the calculated strain values to an unknown degree. As a consequence, strain values obtained at one center are not transferable to another center if these factors are not taken into account. In order to usher CMR feature tracking into clinical practice, acquisition protocols and post-processing methods will have to be standardized and harmonized.

Similar to CMR tissue tracking, myocardial strain can also be assessed with echocardiography using a technique referred to as speckle tracking. Speckle tracking echocardiography is more widely available than CMR and has a higher spatial resolution. On the other hand, it has a lower signal-to-noise ratio and may be hampered by poor acoustic windows. Several studies have investigated the effects

Table 3: Intraclass correlation coefficients of strain measurements

|                | Intraobserver | Interobserver | ANOVA P value |
|----------------|---------------|---------------|---------------|
| Global         | GLS 0.98 (0.97 to 0.99) | 0.97 (0.95 to 0.99) | 0.002 | 0.86 |
|                | GCS 0.99 (0.99 to 1.00) | 0.99 (0.99 to 1.00) | <0.001 | 0.31 |
|                | GRS 0.99 (0.99 to 1.00) | 0.99 (0.99 to 1.00) | 0.003 | 0.67 |
| Regional       | CS 0.95 (0.94 to 0.96) | 0.93 (0.92 to 0.94) | 0.003 | 0.50 |
|                | RS 0.95 (0.95 to 0.96) | 0.93 (0.92 to 0.94) | 0.003 | 0.67 |

Data are intraclass correlation coefficients (95% confidence interval)

GLS global longitudinal shortening, GCS global circumferential shortening, GRS global radial shortening, CS circumferential shortening, RS radial shortening

Table 4: Global LV function, mass and infarct size before and after percutaneous revascularization

|                | All patients (n = 150) | Patients with preserved LV strain (n = 81) | Patients with impaired LV strain (n = 51) | ANCOVA P value |
|----------------|------------------------|------------------------------------------|------------------------------------------|---------------|
|                | Before PCI | After PCI | P value | Before PCI | After PCI | P value | Before PCI | After PCI | P value |
| EDM (mL/m²)    | 99 ± 32 | 95 ± 30 | 0.02 | 85 ± 20 | 82 ± 18 | 0.04 | 118 ± 34 | 118 ± 34 | 0.90 |
| ESV (mL/m²)    | 54 ± 29 | 51 ± 28 | 0.01 | 36 ± 12 | 34 ± 10 | 0.03 | 76 ± 33 | 76 ± 33 | 0.90 |
| EF (%)         | 45 ± 10 | 47 ± 10 | 0.01 | 42 ± 6 | 43 ± 6 | 0.01 | 37 ± 9 | 37 ± 9 | 0.90 |
| GCS (%)        | 14 ± 3.4 | 14 ± 3.4 | 0.90 | 16 ± 3.0 | 16 ± 3.0 | 0.90 | 15 ± 3.5 | 15 ± 3.5 | 0.90 |
| GRSS (%)       | 26 ± 10.4 | 26 ± 10.4 | 0.90 | 24 ± 10.4 | 24 ± 10.4 | 0.90 | 20 ± 10.4 | 20 ± 10.4 | 0.90 |
| LV mass (g/m²) | 52.5 ± 12.6 | 52.5 ± 12.6 | 0.90 | 50 ± 12.1 | 50 ± 12.1 | 0.90 | 50 ± 12.1 | 50 ± 12.1 | 0.90 |
| Infarct size (%) | 4.4 ± 11.8 | 4.4 ± 11.8 | 0.90 | 1.9 ± 0.4 | 1.9 ± 0.4 | 0.90 | 5.0 ± 10.4 | 5.0 ± 10.4 | 0.90 |

Data are mean ± standard deviation, median [interquartile range] or absolute number (%)

EDM end-diastolic volume, ESV end-systolic volume, EF ejection fraction, GCS global circumferential shortening, GRSS global radial shortening, LV left ventricle, SV stroke volume

Preserved LV strain is defined as the combination of GLS ≥ 14.4%, GCS ≥ 15.0% and GRS ≥ 22.1%, whereas impaired LV strain is defined as the combination of GLS < 14.4%, GCS < 15.0% and GRS < 22.1%
of CTO-PCI on LV function using speckle tracking echocardiography [28–33]. Although follow-up in these studies ranged from 1 month to 2 years, the majority documented significant improvements in echocardiography derived strain parameters after CTO-PCI. Contrary to these findings, no improvement in LV strain was observed in the overall cohort of present study. Small but statistically significant improvements in global LV function were however noted among patients with LV dysfunction prior to PCI. Conversely, patients with preserved LV function at baseline demonstrated a slight decrease in GLS. These patients have little to gain from PCI in terms of functional recovery, but may still experience loss of contracting cardiomyocytes due to periprocedural injury. This hypothesis is supported by the observation that infarct size increased after CTO-PCI. GCS and GRS remained unaltered in these patients, which is not...
surprising given that GLS has been documented as being more sensitive to subtle changes in contractility [27]. On a regional level, CS improved in the vascular territory of the CTO but remained unchanged in remote myocardium. Functional recovery after CTO-PCI is consequently a direct result of increased contractility in the vascular territory of the CTO. Functional improvement was most prominent in segments with dysfunction at baseline and was associated with the extent of scar. Surprisingly, strain in dysfunctional segments with > 50% hyperenhancement improved after CTO-PCI similar to the improvement observed in dysfunctional segments with ≤ 50% hyperenhancement.

In summary, LV function did not improve after CTO-PCI. Even in patients with LV dysfunction and myocardial viability at baseline, who are most likely to benefit from revascularization, the functional recovery that could be gained through CTO-PCI was only minor and not clinically relevant. It is therefore unlikely that CTO-PCI will reduce the incidence of heart failure or otherwise significantly improve prognosis for the individual patient through vast improvement of LV function. This should be taken into consideration when scheduling a patient for CTO-PCI, especially given the higher complication rate of CTO-PCI in comparison with regular PCI [4]. CTO-PCI may nevertheless be beneficial

Fig. 3  Relationship between global strain improvement and extent of viability. Scatterplots demonstrating the relationship of improvement in GLS (top), GCS (bottom, left) and GRS (bottom, right) with the percentage of LV that was dysfunctional but viable. CS circumferential shortening, RS radial shortening; other abbreviations as in Fig. 2
Table 5  Regional LV function before and after percutaneous revascularization

| Before PCI | After PCI | P value |
|------------|-----------|---------|
| All segments in CTO territory (N = 790) | | |
| CS (%) | 15.4 [11.2 to 19.8] | 16.0 [11.8 to 19.7] | 0.039 |
| RS (%) | 23.2 [15.1 to 34.1] | 24.3 [15.8 to 33.6] | 0.55 |
| Segments in CTO territory with preserved strain (N = 415) | | |
| CS (%) | 19.6 [17.4 to 22.7] | 19.1 [16.5 to 22.0] | < 0.001 |
| RS (%) | 33.5 [27.5 to 42.7] | 32.0 [25.5 to 41.1] | < 0.001 |
| Dysfunctional segments in CTO territory with < 50% scar (N = 331) | | |
| CS (%) | 11.0 [7.4 to 8.5] | 11.9 [8.5 to 15.0] | < 0.001 |
| RS (%) | 14.8 [9.7 to 18.7] | 16.4 [10.6 to 22.0] | < 0.001 |
| Dysfunctional segments in CTO territory with ≥ 50% scar (N = 32) | | |
| CS (%) | 6.1 [0.7 to 9.8] | 6.9 [4.1 to 13.5] | < 0.001 |
| RS (%) | 7.3 [5.1 to 12.6] | 9.0 [4.9 to 18.4] | 0.001 |
| Remote segments (N = 710) | | |
| CS (%) | 18.7 [14.6 to 22.6] | 18.9 [15.2 to 22.1] | 0.84 |
| RS (%) | 31.0 [21.6 to 42.1] | 31.5 [22.4 to 40.9] | 0.58 |

Data are median [inter-quartile range]

Preserved strain is defined as the combination of CS ≥ 15.0% and RS ≥ 22.1%, whereas dysfunctional is defined as the combination of CS < 15.0% and RS < 22.1%

Table 5 shows the regional LV function before and after percutaneous revascularization. The table includes data for all segments in the CTO territory, segments with preserved strain, segments with ≥ 50% scar, and remote segments. The P values indicate the significance of the changes observed after revascularization.

Study limitations

The follow-up period of 3 months after successful PCI was arbitrary and longer follow-up may have increased the observed improvement in LV function. Moreover, CTO-PCI was not performed in patients without evidence of viability on baseline CMR. Although such a diagnostic work-up is advocated by current guidelines, the exclusion of patients with predominantly transmural scar in the CTO territory may explain the modest relationship between strain improvement and myocardial scar observed in the present study [3]. Finally, the use of a different contrast agent may have improved the delineation between infarcted myocardium, blood pool and non-infarcted myocardium, and increased slice thickness may have resulted in more optimal cine images.

Conclusions

Percutaneous revascularization of CTOs does not improve global longitudinal, circumferential or radial shortening. Even in the subgroup of patients and segments most likely to benefit from revascularization (i.e. LV dysfunction at baseline and no or limited myocardial scar), CTO-PCI failed to
show a clinically relevant improvement in myocardial contractility. It is therefore unlikely that CTO-PCI will favorably affect patient outcomes through recovery of LV function.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s10554-021-02355-4.

**Funding** The authors state that this work has not received any funding.

**Data availability** Data will be made available upon reasonable request.

**Code availability** Yes.

**Declarations**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethical approval** Institutional Review Board approval was obtained.

**Informed consent** Written informed consent was obtained from all individual participants in the study. The authors affirm that the human research participant provided informed consent for publication of the images in Fig. 2.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Tsai TT, Stanislawski MA, Shunk KA, Armstrong EJ, Grunwald GK, Schob AH, Valle JA, Alfonso CE, Nallamothu BK, Ho PM, Rumsfeld JS, Brilakis ES (2017) Contemporary incidence, management, and long-term outcomes of percutaneous coronary interventions for chronic coronary artery total occlusions: insights from the VA CART program. JACC Cardiovasc Interv 10(9):866–875. https://doi.org/10.1016/j.jcin.2017.02.044

2. Werner GS, Gitt AK, Zeymer U, Juenger C, Towae F, Wienerbach H, Senges J (2009) Chronic total occlusion in patients with stable angina pectoris: impact on therapy and outcome in present day clinical practice. Clin Res Cardiol 98(7):435–441. https://doi.org/10.1007/s00392-009-0013-5

3. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Sefirovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO, Group ESC/ESHS (2019) 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 40(2):87–165. https://doi.org/10.1093/eurheartj/ehy394

4. Brilakis ES, Banerjee S, Karmalipouris D, Lombardi WL, Tsai TT, Shunk KA, Kennedy KF, Speratus JA, Holmes DR Jr, Grantham JA (2015) Procedural outcomes of chronic total occlusion percutaneous coronary intervention: a report from the NCDR (National Cardiovascular Data Registry). JACC Cardiovasc Interv 8(2):245–253. https://doi.org/10.1016/j.jcin.2014.08.014

5. Henriques JP, Hoenders LP, Ramunddal T, Laanmets P, Eriksen E, Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, van Rossum AC, Marques KM, Eliaj J, van Dongen IM, Claessen BE, Tijssen JG, van der Schaar RJ, Investigators ET (2016) Percutaneous intervention for concurrent chronic total occlusions in patients with STEMI: the EXPLORE trial. J Am Coll Cardiol 68(15):1622–1632. https://doi.org/10.1016/j.jacc.2016.07.744

6. Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, Rumoroso JR, Egelis G, Christiansen EH, Escaned J, di Mario C, Hovasse T, Teruel L, Bufe A, Lauer B, Boggaerts K, Goicoeia J, Spratt JC, Gershlick AH, Gallassi AR, Louvard Y (2018) A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J 39(26):2484–2493. https://doi.org/10.1093/eurheartj/ehy220

7. Lee SW, Lee PH, Ahn JM, Park DW, Yoon SC, Han S, Kang H, Kang SJ, Kim YH, Lee CW, Park SW, Hur SH, Rha SW, Her SH, Choi SW, Lee BK, Lee NH, Lee JY, Cheong SS, Kim MH, Ahn YK, Lim SW, Lee SG, Hiremath S, Santosio T, Udayachalam W, Cheng JJ, Cohen DJ, Muramatsu T, Tsuikhaine E, Asakura Y, Park SJ (2019) Randomized trial evaluating percutaneous coronary intervention for the treatment of chronic total occlusion. Circulation 139(14):1674–1683. https://doi.org/10.1161/CIRCULATIONAHA.118.031313

8. Baks T, van Geuns RJ, Duncker DJ, Cademartiri F, Mollet NR, Krestin GP, Serruys PW, de Feyter PJ (2006) Prediction of left ventricular function after drug-eluting stent implantation for chronic total coronary occlusions. J Am Coll Cardiol 47(4):721–725. https://doi.org/10.1016/j.jacc.2005.10.042

9. Cheng AS, Selvanayagam JB, Jerosch-Herold M, van Gaal WJ, Karamitsos TD, Neubauer S, Banning AP (2008) Percutaneous treatment of chronic total coronary occlusions improves regional hyperemic myocardial blood flow and contractility: insights from quantitative cardiovascular magnetic resonance imaging. JACC Cardiovasc Interv 1(1):44–53. https://doi.org/10.1016/j.jcin.2007.11.003

10. Kirschbaum SW, Baks T, van den Ent M, Sianos G, Krestin GP, Serruys PW, de Feyter PJ, van Geuns RJ (2008) Evaluation of left ventricular function three years after percutaneous recanalization of chronic total coronary occlusions. Am J Cardiol 101(2):179–185. https://doi.org/10.1016/j.amjcard.2007.07.060

11. Mashayekhi K, Nuhrenberg TG, Toma A, Gick M, Ferenc M, Hochholzer W, Comberg T, Rothe J, Valina CM, Loffelhardt N, Ayoub M, Zhao M, Bremicker J, Jander N, Minners J, Ruile P, Behnes M, Akin I, Schaufele T, Neumann FJ, Buttner HJ (2018) A randomized trial to assess regional left ventricular function after stent implantation in chronic total occlusion: the REVASC trial. JACC Cardiovasc Interv 11(19):1982–1991. https://doi.org/10.1016/j.jcin.2018.05.041

12. Bucciarelli-Ducci C, Auger D, Di Mario C, Locca D, Petryka J, O’Hanlon R, Grasso A, Wright C, Symmonds K, Wage R, Asimacopoulos E, Del Furia F, Lyne JC, Gatehouse PD, Fox KM, Pennell DJ (2016) CMR guidance for recanalization of coronary chronic total occlusion. JACC Cardiovasc Imaging 9(5):547–556. https://doi.org/10.1016/j.jcmg.2015.10.025

13. Stuijfzand WJ, Biesbroek PS, Rajmakers PG, Driessen RS, Schmurchiner SP, van Diemen P, van den Berg J, Nijveldt R, Lamertmsma AA, Walsh SJ, Hanratty CG, Spratt JC, van Rossum AC, Nap A, van Royen N, Knaaen P (2017) Effects of successful percutaneous coronary intervention of chronic total occlusions on...
